 | | Vol. 10.38 – 5 October, 2022 |
| |
|
|
| To identify mutations that confer resistance to a protease inhibitor against protease 3CLpro, investigators engineered a chimeric vesicular stomatitis virus (VSV) that expressed a polyprotein composed of the VSV glycoprotein G, the SARS-CoV-2 3CLpro, and the VSV polymerase L.
[Science Translational Medicine] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Scientists tested human serum panels from participants with differing infection and vaccination status using a multiplex surrogate virus neutralization assay targeting 20 sarbecoviruses.
[Nature Microbiology] |
|
|
|
| Researchers observed increased susceptibility to Omicron infection in household contacts compared to Delta, independent of contacts’ vaccination status.
[Nature Communications] |
|
|
|
| Adults with HIV were enrolled into a single arm open label study. Two doses of ChAdOx1 nCoV-19 were followed twelve months later by a third heterologous vaccine dose.
[Clinical infectious Diseases] |
|
|
|
| Researchers reported the generation and characterization of two potent human monoclonal antibodies, NA8 and NE12, against the receptor-binding domain of the SARS-CoV-2 spike protein.
[Cell Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists identified a cytoplasmic antiviral lncRNA that they named antiviral lncRNA prohibiting human alphaviruses, which was transcriptionally induced by alphaviruses and functions independently of IFN to inhibit the replication of CHIKV and its closest relative, O’nyong’nyong virus, but not other viruses.
[Molecular Cell] |
|
|
|
| Researchers used broad-spectrum oral antibiotics to treat specific pathogen free chickens to deplete the microbiota before infection with nephropathogenic infectious bronchitis virus (IBV) to analyze the impact of microbiota on IBV infections in vivo.
[Microbiome] |
|
|
|
| Scientists reported that monkeypox in this case series was associated with a strong plasma proteomic response among nutritional and acute phase response proteins. They reported a correlation between plasma proteins and disease severity.
[EMBO Molecular Medicine] |
|
|
|
| Meta-analysis combined with subsequent qRT-PCR, western-blotting and flow cytometry assay were used to detect SIRPα expression in pulmonary tuberculosis patients. Cell-based assays were used to explore the regulation of macrophage function by SIRPα.
[Ebiomedicine] |
|
|
|
| Researchers generated a comprehensive transcriptome from multiple tissues of two species of cotton rats that are commonly used as animal models, and compared and contrasted gene expression changes and immune responses to respiratory syncytial virus infection between the two species.
[Scientific Reports] |
|
|
|
| The authors identified combinations of early innate responses that predicted neutralizing antibody responses induced in HIV-Env SOSIP immunized cynomolgus macaques using various routes of vaccine injection and adjuvants.
[Cell Reports Medicine] |
|  |
|
|
|
| Investigators review the nucleic acid–protein granules that were implicated in the innate immune response, discuss general consequences of condensate formation and signal transduction, as well as what outstanding questions remain.
[EMBO Journal] |
|
|
|
| Scientists provide an overview of current knowledge about the humoral immune response to SARS-CoV-2, with a particular focus on the protective and pathological role of humoral immunity in COVID-19 severity.
[Mucosal Immunology] |
|
|
|
|
| Clarametyx Biosciences Inc. announced that the FDA has accepted the company’s IND application to initiate a first-in-human Phase I safety study followed by a Phase Ib trial of CMTX-101, a novel immune-enabling antibody therapy.
[Clarametyx Biosciences, Inc.] |
|
|
|
| Enanta Pharmaceuticals, Inc. announced the initiation of a Phase IIb, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of EDP-938, its novel N-protein inhibitor, in adults with acute respiratory syncytial virus infection who are at high risk of complications.
[Enanta Pharmaceuticals, Inc.] |
|
|
|
|
| December 4 – 7, 2022
Banff, Alberta, Canada |
|
|
|
|
|
| | University of Alberta – Edmonton, Alberta, Canada |
|
|
|
| | University of Calgary – Calgary, Alberta, Canada |
|
|
|
| | University of Stavanger – Stavanger, Norway |
|
|
|
| | University of Wisconsin-Madison – Madison, Wisconsin, United States |
|
|
|
| | University of St Andrews – St Andrews, Scotland, United Kingdom |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
